ZBIO logo

ZBIO Zenas BioPharma, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$23.85
-1.19 (-4.75%)

Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus er…

Market Cap: $1.62Bzenasbio.com

Price

No data yet.

Social Signal Score

60
5d
—
30d
60
2 mentions
—
60d
60
5 mentions
—
90d
60
9 mentions
—
news: 9

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 1Sell 0Strong Sell 0
Avg price target$43.5+82.4%
Low $32Median $43.5High $55
Current Consensus

Revenue

$10.00M
$0.00$16.67M$33.33M$50.00M
Dec 2022Sep 2026

Analyst Estimates

FY2025
$-4.12
$-4.93–$-3.18
2 analysts
FY2026
$-6.25
$-6.28–$-6.21
4 analysts
FY2027
$-5.47
$-5.59–$-5.28
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Leon Oliver Moulder Jr.
Sector
Healthcare
Industry
Biotechnology
Employees
167
Beta
-1.02
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-1.60
zenasbio.com